Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.
Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.
复制标题
DOI:
10.1038/nm.3877
复制
发表时间:
2015-07
期刊:
影响因子:
82.9
通讯作者:
Morrell, Nicholas W.
中科院分区:
文献类型:
--
作者:
Long, Lu;Ormiston, Mark L.;Yang, Xudong;Southwood, Mark;Graef, Stefan;Machado, Rajiv D.;Mueller, Matthias;Kinzel, Bernd;Yung, Lai Ming;Wilkinson, Janine M.;Moore, Stephen D.;Drake, Kylie M.;Aldred, Micheala A.;Yu, Paul B.;Upton, Paul D.;Morrell, Nicholas W.
Genetic evidence implicates the loss of bone morphogenetic protein type II receptor (BMPR-II) signaling in the endothelium as an initiating factor in pulmonary arterial hypertension (PAH). However, selective targeting of this signaling pathway using BMP ligands has not yet been explored as a therapeutic strategy. We identified BMP9 as the preferred ligand for preventing apoptosis and enhancing monolayer integrity in both pulmonary arterial endothelial cells and blood outgrowth endothelial cells from subjects with PAH bearing mutations in BMPR-II. In vivo, we report the spontaneous generation of PAH in a mouse model bearing a heterozygous knock-in of a human BMPR-II mutation, R899X. Administration of BMP9 reversed established PAH in Bmpr2+/R899X mice, as well as in models of disease developed in response to either monocrotaline or VEGF receptor inhibition combined with chronic hypoxia. These results demonstrate the promise of direct enhancement of endothelial BMP signaling as a novel therapeutic strategy for PAH.
登录
查看更多内容
影响因子:
37.8
作者:
Hong KH;Lee YJ;Lee E;Park SO;Han C;Beppu H;Li E;Raizada MK;Bloch KD;Oh SP
通讯作者:
Oh SP
DOI:
10.1165/rcmb.2002-0085oc
发表时间:
2003-05-01
影响因子:
6.4
作者:
Harrington, EO;Brunelle, JL;Rounds, S
通讯作者:
Rounds, S
影响因子:
2.7
作者:
Beppu, H;Kawabata, M;Miyazono, K
通讯作者:
Miyazono, K
影响因子:
3.7
作者:
Frump AL;Lowery JW;Hamid R;Austin ED;de Caestecker M
通讯作者:
de Caestecker M
影响因子:
5.1
作者:
Kang, Q;Sun, MH;He, TC
通讯作者:
He, TC